Fusion Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020
Market Capitalization	1,831	696	141	180	490
Market Cap Growth	-	393.48%	-21.49%	-63.37%	-
Enterprise Value	1,644	511	9	-16	266
PE Ratio	-7.33	-7.33	-1.61	-2.22	-6.15
PS Ratio	884.17	336.47	96.51	124.71	-
PB Ratio	8.22	3.13	0.87	0.78	1.67
P/FCF Ratio	-8.12	-8.12	-1.87	-2.33	-15.87
P/OCF Ratio	-8.51	-8.51	-1.92	-2.37	-16.47
EV/Sales Ratio	794.91	247.21	6.10	-11.37	-
EV/EBITDA Ratio	-6.01	-6.01	-0.10	0.21	-3.54
EV/EBIT Ratio	-5.75	-5.75	-0.10	0.20	-3.51
EV/FCF Ratio	-5.97	-5.97	-0.12	0.21	-8.61
Debt / Equity Ratio	0.23	0.23	0.25	0.03	-
Debt / EBITDA Ratio	-0.59	-0.59	-0.47	-0.08	-
Debt / FCF Ratio	-0.59	-0.59	-0.53	-0.09	-
Quick Ratio	14.48	14.48	11.44	16.23	18.92
Current Ratio	15.01	15.01	11.88	16.93	19.24
Asset Turnover	0.01	0.01	0.01	0.01	0
Interest Coverage	-17.22	-17.22	-48.67	-	-
Return on Equity (ROE)	-46.60%	-46.60%	-46.10%	-31.80%	-36.60%
Return on Assets (ROA)	-35.30%	-35.30%	-38.00%	-29.50%	-31.30%
Return on Capital (ROIC)	-36.37%	-36.37%	-43.48%	-34.43%	-12.88%
Earnings Yield	-5.19%	-13.64%	-62.14%	-45.13%	-16.26%
FCF Yield	-4.69%	-12.32%	-53.49%	-43.00%	-6.30%
Buyback Yield / Dilution	-49.98%	-49.98%	-2.70%	-93.34%	-1050.20%
Total Shareholder Return	-49.98%	-49.98%	-2.70%	-93.34%	-1050.20%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).